We believe that we can more effectively treat people by improving the way we understand and diagnose disease. Our research is aimed at discovering new ways of diagnosing and treating viral and bacterial infections, as well as diseases associated with chronic inflammation such as asthma, chronic obstructive pulmonary disease, type 2 diabetes, Parkinson’s, Alzheimer’s, cardiovascular disease and cancer.

We have a major focus on the design and development of novel antibiotics active against drug-resistant bacteria, also known as ‘superbugs’.  Prof. Cooper has founded 4 companies and continues to spin-off innovative ideas from medical research and basic science to translate them into new therapies to help people in need.

Traineeships, honours and PhD projects include

  • Antibacterial and antifungal medicinal chemistry
  • Small molecule inhibitors of inflammation that drives chronic diseases
  • Antibiotic mode of action studies
  • Chemoinformatics, microbiology and nanotechnology for diagnostics.

For project enquiries please contact: Dr Mark Baskovich or Dr Avril Robertson

Project members

Group Leader

Professor Matt Cooper

Director, IMB Centre for Superbug Solutions
Professorial Research Fellow
Institute for Molecular Bioscience